Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263386 | 0.91 | CYP2D6 (0.46) | TLR8CYP2D6GPR119USP2SMN1; SMN2 | |
| SCHEMBL345594 | 0.88 | CCR5 (0.41) | TLR8CYP2D6GPR119DRD2DRD3 | |
| SCHEMBL30234012 | 0.87 | GPR119 (0.43) | TLR8CYP2D6GPR119USP2SMN1; SMN2 | |
| SCHEMBL4543892 | 0.86 | TLR8 (0.55) | TLR8USP2SMN1; SMN2CNR2 | |
| SCHEMBL20353659 | 0.85 | CYP2D6 (0.48) | CYP2D6GPR119USP2SMN1; SMN2 | |
| SCHEMBL25028575 | 0.85 | CYP2D6 (0.44) | TLR8CYP2D6GPR119DRD2USP2 | |
| SCHEMBL30772318 | 0.84 | CYP2D6 (0.44) | CYP2D6GPR119USP2SMN1; SMN2CCR5 | |
| SCHEMBL30049604 | 0.84 | CYP2D6 (0.44) | CYP2D6GPR119USP2SMN1; SMN2CCR5 | |
| SCHEMBL10263110 | 0.83 | USP2 (0.43) | CYP2D6GPR119USP2SMN1; SMN2 | |
| SCHEMBL10264330 | 0.83 | CYP11B2 (0.46) | CYP2D6GPR119USP2SMN1; SMN2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| US-8609681-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | TLR8 3990/4885CYP2D6 644/4885GPR119 4318/4885 |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | TLR8 3990/4885CYP2D6 644/4885GPR119 4318/4885 |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | TLR8 3990/4885CYP2D6 644/4885GPR119 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.